Comparative Pharmacology
Head-to-head clinical analysis: CLOFARABINE versus IDVYNSO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOFARABINE versus IDVYNSO.
CLOFARABINE vs IDVYNSO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.
IDVYNSO is a selective dopamine D3 receptor antagonist, which modulates dopaminergic neurotransmission in the mesolimbic pathway.
52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.
5 mg/kg IV once daily for 14 days; then 2.5 mg/kg IV once daily for 14 days.
None Documented
None Documented
Terminal elimination half-life: 5.2 hours (range 4-6 hours) in adult patients; clinically, this supports a 5-day continuous infusion schedule
Clinical Note
moderateClofarabine + Digoxin
"Clofarabine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateClofarabine + Digitoxin
"Clofarabine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateClofarabine + Deslanoside
"Clofarabine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateClofarabine + Acetyldigitoxin
"Clofarabine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is 12–18 hours, supporting twice-daily dosing in patients with normal renal function.
Renal: 49-60% as unchanged drug; biliary/fecal: minimal (<1%)
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30%, with the remainder metabolized.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent